Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-072013
Filing Date
2025-05-15
Accepted
2025-05-15 08:00:11
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8285
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 85447
  Complete submission text file 0000950170-25-072013.txt   128224
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Subject) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-51477 | Film No.: 25948797
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 40 10TH AVENUE 7TH FLOOR NEW YORK NY 10014
Business Address 40 10TH AVENUE 7TH FLOOR NEW YORK NY 10014 646-597-6980
RTW INVESTMENTS, LP (Filed by) CIK: 0001493215 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G